From Nasdaq: 2025-06-16 09:49:00

Roche (RHHBY) moves prasinezumab to phase III for early Parkinson’s disease. Data from phase IIb study and ongoing extensions support the decision. Shares rise by 20.9% YTD, outperforming the industry.

Prasinezumab targets alpha-synuclein, a key Parkinson’s progression driver. Ongoing studies evaluate long-term safety and efficacy in early-stage patients. Positive trends in PADOVA study hint at disease-modifying potential.

Roche believes prasinezumab could be the first disease-modifying Parkinson’s treatment. Licensing agreement with Prothena includes double-digit royalties on net sales. Prothena earns $135M with potential for $620M in milestones.

UCB’s minzasolmin study with Novartis fails, highlighting the challenges in Parkinson’s treatment development. Roche’s success with prasinezumab could be significant for the company.

Roche (RHHBY) holds a Zacks Rank #3. Novartis and Bayer, both Zacks Rank #2, show promising growth. Analysts project strong revenue increase for a satellite-based communications firm.

Zacks’ top stock pick holds potential for significant growth. Novartis and Bayer show positive earnings trends. Download Zacks’ 7 Best Stocks report for more insights.



Read more at Nasdaq: RHHBY to Advance Parkinson’s Disease Drug to Late-Stage Development